Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 proof-of-concept, dose escalation study of BLU-5937 in patients with chronic cough

Trial Profile

A phase 2 proof-of-concept, dose escalation study of BLU-5937 in patients with chronic cough

Planning
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs BLU-5937 (Primary)
  • Indications Cough
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 19 Nov 2018 According to a BELLUS Health media release, Dr. Jaclyn Smith, Professor of Respiratory Medicine at the University of Manchester will be the principal investigator of the study.
    • 19 Nov 2018 According to a BELLUS Health media release, the company expects to start this study in mid-2019. Top-line results are expected in mid-2020
    • 03 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top